SynthesisBMC cancer2016
Prognostic significance of p53 expression in patients with esophageal cancer: a meta-analysis.
Synthesis in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 4 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Verrucous esophageal carcinoma is a unique indolent subtype of squamous cell carcinoma: a systematic review and individual patient regression analysis.Journal of gastroenterology · 2021Pooled it
- The association between dietary protein intake and esophageal cancer risk: a meta-analysis.Bioscience reports · 2020Pooled it
- Effect of dietary cholesterol intake on the risk of esophageal cancer: a meta-analysis.The Journal of international medical research · 2019Pooled it
- Pooled it
- AssessingNuclear medicine and molecular imaging · 2025Article
- Prognostic markers in oesophageal and gastric cancer review. Are they ready for clinical practice?ESMO gastrointestinal oncology · 2024Review
- Esophageal Mucosal Resistance in Reflux Esophagitis: What We Have Learned So Far and What Remains to Be Learned.Diagnostics (Basel, Switzerland) · 2023Review
- p53/Cancers · 2023Article
- Clinicopathologic characterization of cervical metastasis from an unknown primary tumor: a multicenter study in Korea.Journal of pathology and translational medicine · 2023Article
- The High Expression of p53 Is Predictive of Poor Survival RatherJournal of oncology · 2023Article
- Reactivation of mutant p53 in esophageal squamous cell carcinoma by isothiocyanate inhibits tumor growth.Frontiers in pharmacology · 2023Article
- Exploring the use of p53 protein expression as an indicator of oesophageal cancer severity from a high incidence rural area of Africa.African health sciences · 2022Article
- Exploring the use of p53 protein expression as an indicator of oesophageal cancer severity from a high incidence rural area of Africa.African health sciences · 2022Article
- p53 Immunohistochemistry and Mutation Types Mismatching in High-Grade Serous Ovarian Cancer.Diagnostics (Basel, Switzerland) · 2022Article
- Telomerase inhibition decreases esophageal squamous carcinoma cell migration and invasion.Oncology letters · 2020Article
- Association between TP53 gene deletion and protein expression in esophageal squamous cell carcinoma and its prognostic significance.Oncology letters · 2020Article
- p53 overexpression is a prognosticator of poor outcome in esophageal cancer.Oncology letters · 2019Article
- Prognostic alternative splicing signatures and underlying regulatory network in esophageal carcinoma.American journal of translational research · 2019Article
- DpdtbA-Induced Growth Inhibition in Human Esophageal Cancer Cells Involved Inactivation of the p53/EGFR/AKT Pathway.Oxidative medicine and cellular longevity · 2019Article
- TP53 Mutation in Correlation to Immunohistochemical Expression of P53 Protein in Patients with Hepatocellular Carcinoma.Open access Macedonian journal of medical sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic value of p53 protein expression in esophageal cancer has been evaluated, but the results remain inconclusive and no consensus has yet been achieved. This meta-analysis was conducted to quantitatively assess the prognostic significance of p53 expression in esophageal cancer.
methodsPublications that assessed the clinical or prognostic significance of p53 expression in esophageal cancer and were published before July 1, 2015 were identified by searching the PubMed and EMBASE databases. A meta-analysis was performed to clarify the association between p53 expression and the clinical outcomes.
resultsA total of 36 publications met the criteria and included 4577 cases. Analysis of these data showed that p53 expression in esophageal cancer was significantly associated with poorer 5-year survival (RR = 1.30, 95 % CI: 1.11-1.51, P = 0.0008). Subgroup analyses according to histological type, continent of the patients, and cut-off value revealed the similar results. The results also indicated that p53 expression was highly associated with advanced TNM stages (I/II vs. III/IV, OR = 0.74, 95 % CI: 0.55-0.99, P = 0.04), lymph node metastasis (OR = 0.77, 95 % CI: 0.66-0.90, P = 0.001), and distant metastasis (OR = 0.46, 95 % CI: 0.26-0.80, P = 0.006). However, p53 expression in the included studies was not significantly associated with tumor size (≤ 5 cm vs. > 5 cm, OR = 1.13, 95 % CI: 0.92-1.40, P = 0.24), tumor location (upper + middle vs. lower, OR = 0.91, 95 % CI: 0.70-1.17, P = 0.45), grade of differentiation (well + moderate vs. poor, OR = 1.10, 95 % CI: 0.90-1.34, P = 0.35), and the depth of invasion (T1/T2 vs. T3/T4, OR = 0.86, 95 % CI: 0.71-1.03, P = 0.09).
conclusionsThis meta-analysis showed that p53 expression may be a useful biomarker for predicting poorer prognosis in patients with esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.